協和発酵バイオ（株）

Kyowa Hakko Bio Singapore is a subsidiary of Kirin Holdings Co. Ltd., specializing in health science. The company aims to revolutionize the healthcare industry by shifting the focus from treatment to prevention through the development and application of patented fermentation technology. Since 1949, Kyowa Hakko Bio has been at the forefront of pioneering high-quality health-enhancing ingredients such as “Kyowa Quality” amino acids, nucleic acids, branded ingredients, postbiotics, and human milk oligosaccharides. These ingredients are utilized in supplements and functional foods, supported by robust clinical documentation, to contribute to the health and well-being of individuals globally. With its headquarters in Singapore, the company has positioned itself as a global leader in specialty fermentation and research. Although specific funding details are not available, Kyowa Hakko Bio's innovative approach and commitment to improving lives through health science make it a compelling prospect for potential investors looking to tap into the evolving landscape of preventive healthcare solutions.